Published Date: 31-Oct-2022
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report, published by KBV research, The Global Blood Plasma Derivatives Market size is expected to reach $72.5 billion by 2028, rising at a market growth of 9.3% CAGR during the forecast period.
The Hemophilia market is experiencing a CAGR of 9.8% during (2022 - 2028). Hemophilia is often a hereditary condition characterized by improper blood clotting. This can result in spontaneous bleeding along with bleeding after injury or surgery. Blood includes several proteins known as clotting factors that aid in stopping bleeding.
The Hospitals market is generating high revenue in the Global Blood Plasma Derivatives Market by End User in 2021; thereby, achieving a market value of $41.8 Billion by 2028. The segment is experiencing a significant growth rate owing to the rise in the prevalence of chronic and infectious diseases, such as immunodeficiency disorder and hemophilia, and the initiatives are taken by public and private entities to advance the healthcare sector.
The Albumin market is showcasing a CAGR of 9% during (2022 - 2028). The growth of the segment is increasing as a result of the rising demand for plasma-derived albumin due to its efficiency in preventing the fluid in blood vessels to drain. Albumin is a liver-produced protein. Albumin enters the circulation and aids in preventing fluid leakage from blood vessels to other tissues.
The North America market dominated the Global Blood Plasma Derivatives Market by Region in 2021; thereby, achieving a market value of $27.3 Billion by 2028. The Europe market is exhibiting a CAGR of 9.1% during (2022 - 2028). Additionally, The Asia Pacific market would witness a CAGR of 9.7% during (2022- 2028).
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Bayer AG, Takeda Pharmaceutical Company Limited, Grifols, S.A., Biotest AG, LFB S.A., CSL Limited, Octapharma AG, Kedrion S.p.A, Sanofi S.A. and Fusion Health Care Pvt. Ltd.
By End User
Unique Offerings from KBV Research